<DOC>
	<DOCNO>NCT01504906</DOCNO>
	<brief_summary>The purpose study assess effect Cyclosporine blood level Ticagrelor .</brief_summary>
	<brief_title>Study Assess Effect Cyclosporine Blood Levels Ticagrelor</brief_title>
	<detailed_description>A Single-Center , Open-Label , Randomized,3-Treatment,3-Period Cross-Over Study Investigate Potential Effect Cyclosporine Pharmacokinetics , Safety , Tolerability Ticagrelor Effect Ticagrelor Pharmacokinetics , Safety , Tolerability Cyclosporine .</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Provision sign date write informed consent prior studyspecific procedure Healthy male subject age 18 45 year ( inclusive ) suitable vein cannulation repeat venipuncture History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug A history hemophilia , von Willebrand 's disease , lupus anticoagulant , diseases/syndromes either alter increase propensity bleed A personal history vascular abnormality include aneurysm ; personal history severe hemorrhage , hematemesis , melena , hemoptysis , severe epistaxis , severe thrombocytopenia , intracranial hemorrhage , rectal bleeding within 1 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy male volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>Bioavailability ( plasma AUC , Cmax , plasma AUC0-t , t1/2Î»z , tmax )</keyword>
</DOC>